Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505175 | 0.88 | AKR1C3 (0.41) | KMT2AMEN1CLEC4MCYP1A2CYP3A4 | |
| SCHEMBL6778119 | 0.79 | KDM4E (0.35) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL6305765 | 0.79 | MAPT (0.48) | KMT2AMEN1CLEC4MCYP1A2CYP3A4 | |
| SCHEMBL4903460 | 0.79 | BRD4 (0.50) | KMT2AMEN1CLEC4MCYP1A2CYP3A4 | |
| SCHEMBL6507421 | 0.79 | AKR1C3 (0.38) | KMT2AMEN1CLEC4MCYP1A2CYP3A4 | |
| SCHEMBL6773220 | 0.74 | MAOB (0.42) | KMT2AMEN1LMNAPOLBMAPT | |
| SCHEMBL6767790 | 0.74 | NPC1 (0.48) | KMT2AMEN1CYP1A2LMNAPOLB | |
| SCHEMBL394742 | 0.71 | KDM4E (0.49) | KMT2AMEN1CLEC4MCYP1A2CYP3A4 | |
| SCHEMBL15328780 | 0.69 | BRD4 (0.63) | KMT2AMEN1CYP1A2CYP2C19LMNA | |
| SCHEMBL7392509 | 0.69 | GABRA1 (0.41) | KMT2AMEN1CLEC4MCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4824965-A | 4-oxo-4,5,6,7-Tetrahydroindole derivatives | BOEHRINGER MANNHEIM GMBH (DE) | 1989-04-25 | — | — | US | claimed |
| US-6720339-B2 | SUCH AS N-PHENYL-4-OXO-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO-1H-INDOLE-3-CARBOXAMIDE; FOR DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2002-12-26 | — | — | US | disclosed |
| US-6353109-B2 | PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS; COGNITION ACTIVATORS | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | disclosed |
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | ALBAUGH PAMELA (US) | 2001-09-06 | — | — | US | disclosed |
| EP-0888300-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034870-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-25 | — | — | WO | disclosed |
| US-4824965-A | 4-oxo-4,5,6,7-Tetrahydroindole derivatives | BOEHRINGER MANNHEIM GMBH (DE) | 1989-04-25 | — | — | US | disclosed |
| US-4736043-A | Process for the preparation of indole derivatives | BOEHRINGER MANNEHEIM GMBH (DE) | 1988-04-05 | — | — | US | disclosed |
| EP-0081137-B1 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES, THEIR USE AS INTERMEDIATES, AND 4-HYDROXY INDOLES | Roche Diagnostics GmbH (DE) | 1986-08-06 | — | — | EP | disclosed |
| EP-0081137-A2 | Process for the preparation of indole derivatives, their use as intermediates, and 4-hydroxy indoles | Roche Diagnostics GmbH (DE) | 1983-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | GABRA1, GABRA4, GABRA2 | KMT2A 408/4885MEN1 3579/4885CLEC4M 4070/4885 |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | CNR1, HTR1A, GABRA6 | KMT2A 351/4885MEN1 2856/4885CLEC4M 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.